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21.6% pt in normal troponin T group had poor outcome (P value
0.0146). After 30 days follow up 50% pt died in elevared troponin
group while only 13.5% pt died in normal troponin group (P value
0.0389).
Conclusion: In patients of acute ischemic stroke with raised
troponin T level there was increased morbidity (P value 0.0146)
and mortality (P value 0.0146) which was found to be statistically
significant.
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Background: Although warfarin has been extensively studied in
clinical trials, little is known about rates of hemorrhage attribut-
able to its use in routine clinical practice. Our objective was to
examine incident hemorrhagic events in a municipal hospital
based cohort of patients with atrial fibrillation who were started
treatment with warfarin.
Methods: We conducted a municipal hospital based cohort study
involving patients (age  50 yr) with atrial fibrillation who started
taking warfarin between Jan 2013, and March 2014. We defined a
major hemorrhage as any visit to hospital for hemorrage. We
determined crude rates of hemorrhage duringwarfarin treatment,
overall and stratified by CHADS 2 score (congestive heart failure,
hypertension, age  75 yr, diabetes mellitus and prior stroke,
transient ischemic attack or thromboembolism).
Results: We included 469 patients with atrial fibrillation who
started treatment with warfarin during the study period. Overall,
the rate of hemorrhage was 3.5% (95% confidence interval [CI]
3.8%e3.9%) per person-year. The risk of major hemorrhage was
highest during the first 30 days of treatment. During this period,
rates of hemorrhage were 11.6% (95% CI 11.1%e12.5%) per person-
year in all patients and 15.6% (95% CI 14.3%e19.4%) per person-
year among patients with a CHADS 2 scores of 4 or greater. Over
the 13months follow-up, 38 patients (8.1%) visited the hospital for
hemorrhage; of these patients, 2 (5%) died in hospital.
Conclusions: In this municipal hospital based cohort of older pa-
tients with atrial fibrillation, we found that rates of hemorrhage
are highest within the first 30 days of warfarin therapy. These
rates are considerably higher than the rates of 1%e3% reported in
randomized controlled trials of warfarin therapy. Our study pro-
vides timely estimates of warfarin-related adverse events that
may be useful to clinicians, patients and policy-makers as new
options for treatment become available.
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Background: It is said pulmonary embolism is “a great imitator”. It
can present with different characteristics which can vary from
patient to patient in young vs elderly patients. Pulmonary embo-
lism (PE) is a blockage of the main pulmonary artery or one of its
branches by a substance that has travelled from elsewhere in the
body through the bloodstream. PE most commonly results from
deep vein thrombosis.
Symptoms of pulmonary embolism include dyspnea, tachy-
cardia, tachypnea, chest pain, palpiations, cyanosis, hypotension,
and sudden death. Diagnosis is based on these clinical findings
and imaging studies, usually CT pulmonary angiography. Treat-
ment is typically with anticoagulation. Severe cases may require
thrombolysis or may require catheter based intervention via
pulmonary thrombectomy.
Objective: The purpose of this study is to assess frequency, risk
factors, presenting symptoms, treatment, complications and In-
hospital outcomes of pulmonary embolism in young patients
compared with those of elderly patients.
Methods: We studied 18 patients of pulmonary embolism in < 40
years age group and 20 patients age more than 40 years admitted
in our hospital from August 2012 to July 2014.Patients with a
diagnosis of pulmonary embolism admitted to between January
2012 and January 2014 were included in this study. A diagnosis of
pulmonary embolsim was based on: chest pain, electrocardio-
graphic changes 2 D ECHO, D dimer, and typical time related
pattern of ABG, ECG, CT Pulmonary angiography and response to
treatment.
Results: Breathlessness was the most common presentation in 30
patients (78.92%), while chest pain in 6 patients(15.2%) and hy-
potension in 2 patients(5.7%). Incidence ofpulmonary embolism is
exceedingly higher inmales (78.92%) compared to females.Typical
symptoms seen in 70%.Risk factors such as prolonged bed rest,
immobilisation levels are more common in elderly patient-
s,whereas family history (22.10%) and diabetes(11.59%) are less
frequent.Prevalence of chest pain is almost same in younger
(76.81%) and elderly(78.6%) age group,most common sign being
tachypnea .74.25% of young patients with pulmonary embolism
received treatment in form of thrombolysis, most of the patiens
(85%) received streotokinase ,15% patients received tenectaplace.
4 patients received intrapulmonary thrombolysis with guidance
of catheter in PA.
Total 5 patients died, most of due to refractory hypotension .2
patients developed chronic pulmonary thromboembolism.
Elevated serum homocysteine levels are seen in 28(10.14%) of
young patients.Primary thrombolysis had good outcome in < 40
years age group.Postprocedure complications are almost negli-
gible ( < 3%) in young age group.The incidence of in-hospital
congestive heart failure, and major bleeding were lowest(<2%) in
the youngest age group.
Conclusion: Younger patients have better outcome as compared
to elderly patients.
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Background: The Incidence of Acute pulmonary thromboembo-
lism, as one of the post operative fatal complications, is around
1.6%. Management of embolism in postoperative cases is always
difficult and thus leading onto high rates of mortality and poor
prognosis. According to ESC guidelines, the use of Tenectaplase is
an important determining factor in the prognosis and
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